BR9913680A - Composições terapêuticas (ii) - Google Patents
Composições terapêuticas (ii)Info
- Publication number
- BR9913680A BR9913680A BR9913680-5A BR9913680A BR9913680A BR 9913680 A BR9913680 A BR 9913680A BR 9913680 A BR9913680 A BR 9913680A BR 9913680 A BR9913680 A BR 9913680A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic compositions
- acceptable ketosis
- ketosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
"COMPOSIçõES TERAPêUTICAS (II)" Composições contendo corpos cetona e/ou seus precursores metabólicos são proporcionadas as quais são adequadas para a administração a humanos e animais e que possuem propriedades de, dentre outras, (i) aumentar eficiência cardíaca, particularmente a eficiência no uso da glicose, (ii) para proporcionar fonte de energia, particularmente em estados de diabetes e insulino-resistentes e (iii) tratar distúrbios causados por danos às células cerebrais, particularmente através do retardamento ou prevenção dos danos cerebrais em áreas cerebrais associadas à memória tal como os encontrados em Alzheimer e condições similares. Estas composições podem ser tomadas como auxiliares nutricionais, por exemplo para atletas, ou para o tratamento de condições médicas, particularmente aquelas associadas com fraca eficiência cardíaca, insulino-resistência e danos neuronais. A invenção adicionalmente proporciona métodos de tratamento e novos ésteres e polímeros para a inclusão nas composições da invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10037198P | 1998-09-15 | 1998-09-15 | |
PCT/US1999/021015 WO2000015216A1 (en) | 1998-09-15 | 1999-09-15 | Therapeutic compositions (ii) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913680A true BR9913680A (pt) | 2001-06-05 |
Family
ID=22279402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913680-5A BR9913680A (pt) | 1998-09-15 | 1999-09-15 | Composições terapêuticas (ii) |
Country Status (18)
Country | Link |
---|---|
US (2) | US20010014696A1 (pt) |
EP (1) | EP1123094B1 (pt) |
JP (1) | JP2002524506A (pt) |
KR (1) | KR100805490B1 (pt) |
CN (1) | CN1273129C (pt) |
AT (1) | ATE359069T1 (pt) |
AU (1) | AU767238B2 (pt) |
BR (1) | BR9913680A (pt) |
CA (1) | CA2339941A1 (pt) |
DE (1) | DE69935799T2 (pt) |
DK (1) | DK1123094T3 (pt) |
ES (1) | ES2283133T3 (pt) |
HK (1) | HK1035665A1 (pt) |
NZ (1) | NZ509739A (pt) |
PT (1) | PT1123094E (pt) |
RU (1) | RU2242227C2 (pt) |
WO (1) | WO2000015216A1 (pt) |
ZA (1) | ZA200101260B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
EP2319508A1 (en) * | 2000-05-01 | 2011-05-11 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
CN1972698B (zh) * | 2003-09-01 | 2010-06-02 | 有限会社爱泽世 | β-羟基短-中链脂肪酸聚合物 |
US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
ES2574557T3 (es) * | 2004-09-21 | 2016-06-20 | Btg International Limited | Miméticos dopaminérgicos |
GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
EP1915144A4 (en) | 2005-06-20 | 2009-08-19 | Accera Inc | METHOD FOR REDUCING OXIDATIVE DAMAGE AND IMPROVING MITOCHONDRIA EFFICIENCY |
LT2500017T (lt) | 2006-04-03 | 2017-12-11 | Accera, Inc. | Ketogeninių junginių panaudojimas senatvinio atminties susilpnėjimo gydymui |
WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
JP5504534B2 (ja) * | 2007-03-30 | 2014-05-28 | 有限会社アーザス | ケトン体生成促進剤組成物 |
RU2459624C2 (ru) * | 2007-04-12 | 2012-08-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Защитные композиции от ишемии/реперфузии и способы применения |
CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
ES2556535T3 (es) | 2007-07-31 | 2016-01-18 | Accera, Inc. | Uso de ensayo genómico y compuestos cetogénicos para tratamiento de una función cognitiva reducida |
CA2702577A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
AU2009266869B2 (en) | 2008-07-03 | 2016-07-07 | Cerecin Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
KR20110115589A (ko) | 2009-01-24 | 2011-10-21 | 파이토팜 피엘씨 | 신경영양인자가 매개된 장애의 치료 |
WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
KR20130043197A (ko) | 2010-07-20 | 2013-04-29 | 파이토팜 피엘씨 | 엘-도파, 도파민 효능제 및/또는 도파민 증강제 유도된 장애의 치료 |
ES2752030T3 (es) | 2012-11-05 | 2020-04-02 | Us Health | Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
AU2014230120B2 (en) | 2013-03-14 | 2018-06-21 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Process for producing (R)-3hydroxybutyl (R)-3hydroxybutyrate |
BR112015024186B1 (pt) | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
KR102610870B1 (ko) | 2016-12-21 | 2023-12-06 | 우니베르지태츠-킨데르슈피탈 바이더 바젤 | 편두통 예방 및 치료 |
KR20190099469A (ko) * | 2016-12-23 | 2019-08-27 | 카트호리이케 유니버시타이트 로이펜 | 중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트 |
US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
BR112023025213A2 (pt) | 2021-07-17 | 2024-02-27 | Ketoswiss Ag | Combinação de um corpo cetônico ou composto cetogênico com um analgésico ou antioxidante |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0522422A3 (en) * | 1991-07-01 | 1993-03-17 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | 3−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
AU6513298A (en) * | 1997-03-17 | 1998-10-12 | British Technology Group Limited | Therapeutic compositions |
US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
CA2317314C (en) * | 1998-01-07 | 2003-12-30 | Metabolix, Inc. | Animal nutrition compositions |
DE69922206T2 (de) * | 1998-07-22 | 2005-11-24 | Metabolix, Inc., Cambridge | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere |
-
1999
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active IP Right Cessation
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
- 1999-09-15 EP EP99946906A patent/EP1123094B1/en not_active Expired - Lifetime
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en active IP Right Grant
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
- 2001-08-28 HK HK01106060A patent/HK1035665A1/xx not_active IP Right Cessation
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
PT1123094E (pt) | 2007-06-28 |
DK1123094T3 (da) | 2007-08-20 |
EP1123094B1 (en) | 2007-04-11 |
US20040171671A1 (en) | 2004-09-02 |
HK1035665A1 (en) | 2001-12-07 |
EP1123094A1 (en) | 2001-08-16 |
CN1316902A (zh) | 2001-10-10 |
EP1123094A4 (en) | 2001-10-04 |
DE69935799T2 (de) | 2007-12-27 |
CN1273129C (zh) | 2006-09-06 |
AU767238B2 (en) | 2003-11-06 |
ES2283133T3 (es) | 2007-10-16 |
NZ509739A (en) | 2003-10-31 |
CA2339941A1 (en) | 2000-03-23 |
US7351736B2 (en) | 2008-04-01 |
JP2002524506A (ja) | 2002-08-06 |
WO2000015216A1 (en) | 2000-03-23 |
US20010014696A1 (en) | 2001-08-16 |
KR100805490B1 (ko) | 2008-02-20 |
ATE359069T1 (de) | 2007-05-15 |
AU5921299A (en) | 2000-04-03 |
DE69935799D1 (de) | 2007-05-24 |
RU2242227C2 (ru) | 2004-12-20 |
ZA200101260B (en) | 2001-08-16 |
KR20010079830A (ko) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913680A (pt) | Composições terapêuticas (ii) | |
DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
MX9203543A (es) | Medicamento. | |
RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
NL300382I1 (nl) | Treatment of pompe's disease | |
MY130157A (en) | Method of use for inhibiting bone loss and lowering serum cholesterol | |
CA2223403A1 (en) | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds | |
NO20004311L (no) | Farmasøytisk sammensetning av topiramat | |
IL99699A0 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
ATE262909T1 (de) | Intravenöse alendronatformulierungen | |
SE8704248D0 (sv) | Medical use | |
DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
KR900015718A (ko) | 골관절염 치료제 | |
RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
SE8500996D0 (sv) | Method of treatment | |
EE9700231A (et) | Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks | |
DE3688787D1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
Dressler et al. | Tic of the respiratory muscles: Report of three cases and review of literature | |
ATE207353T1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
Kaldor et al. | Enhancement of methyldopa metabolism with barbiturate | |
SU944583A1 (ru) | Способ реабилитации травматических поражений мышц | |
DK601788D0 (da) | Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme | |
UA30251A (uk) | Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи | |
UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO APRESENTA REIVINDICACOES QUE NAO ATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O E ARTIGO 13 DA LEI 9279/96 ) E QUE NAO ESTAO SUFICIENTEMENTE DESCRITAS E FUNDAMENTADAS NO RELATORIO DESCRITIVO ( ARTIGOS 24 E 25 DA LEI 9279/96 ). |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |